Checkpoint Therapeutics Stock Market Value
| CKPT Stock | USD 3.47 0.09 2.66% |
| Symbol | Checkpoint |
Checkpoint Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Checkpoint Therapeutics. If investors know Checkpoint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Checkpoint Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share 0.002 | Quarterly Revenue Growth 0.323 | Return On Assets (3.17) | Return On Equity (12.20) |
The market value of Checkpoint Therapeutics is measured differently than its book value, which is the value of Checkpoint that is recorded on the company's balance sheet. Investors also form their own opinion of Checkpoint Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Checkpoint Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Checkpoint Therapeutics' market value can be influenced by many factors that don't directly affect Checkpoint Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Checkpoint Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Checkpoint Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Checkpoint Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Checkpoint Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Checkpoint Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Checkpoint Therapeutics.
| 10/23/2024 |
| 11/22/2024 |
If you would invest 0.00 in Checkpoint Therapeutics on October 23, 2024 and sell it all today you would earn a total of 0.00 from holding Checkpoint Therapeutics or generate 0.0% return on investment in Checkpoint Therapeutics over 30 days. Checkpoint Therapeutics is related to or competes with Lyra Therapeutics, Hookipa Pharma, SAB Biotherapeutics, Cadrenal Therapeutics,, Monopar Therapeutics, Spero Therapeutics, and Bolt Biotherapeutics. Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, d... More
Checkpoint Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Checkpoint Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Checkpoint Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.56 | |||
| Information Ratio | 0.1595 | |||
| Maximum Drawdown | 19.17 | |||
| Value At Risk | (5.73) | |||
| Potential Upside | 7.69 |
Checkpoint Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Checkpoint Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Checkpoint Therapeutics' standard deviation. In reality, there are many statistical measures that can use Checkpoint Therapeutics historical prices to predict the future Checkpoint Therapeutics' volatility.| Risk Adjusted Performance | 0.1513 | |||
| Jensen Alpha | 0.7157 | |||
| Total Risk Alpha | 0.2115 | |||
| Sortino Ratio | 0.1725 | |||
| Treynor Ratio | (62.68) |
Checkpoint Therapeutics Backtested Returns
Checkpoint Therapeutics appears to be slightly risky, given 3 months investment horizon. Checkpoint Therapeutics secures Sharpe Ratio (or Efficiency) of 0.19, which signifies that the company had a 0.19% return per unit of standard deviation over the last 3 months. By analyzing Checkpoint Therapeutics' technical indicators, you can evaluate if the expected return of 0.75% is justified by implied risk. Please makes use of Checkpoint Therapeutics' mean deviation of 3.02, and Risk Adjusted Performance of 0.1513 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Checkpoint Therapeutics holds a performance score of 15. The firm shows a Beta (market volatility) of -0.0114, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Checkpoint Therapeutics are expected to decrease at a much lower rate. During the bear market, Checkpoint Therapeutics is likely to outperform the market. Please check Checkpoint Therapeutics' standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Checkpoint Therapeutics' price patterns will revert.
Auto-correlation | 0.28 |
Poor predictability
Checkpoint Therapeutics has poor predictability. Overlapping area represents the amount of predictability between Checkpoint Therapeutics time series from 23rd of October 2024 to 7th of November 2024 and 7th of November 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Checkpoint Therapeutics price movement. The serial correlation of 0.28 indicates that nearly 28.0% of current Checkpoint Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.28 | |
| Spearman Rank Test | -0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Checkpoint Therapeutics lagged returns against current returns
Autocorrelation, which is Checkpoint Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Checkpoint Therapeutics' stock expected returns. We can calculate the autocorrelation of Checkpoint Therapeutics returns to help us make a trade decision. For example, suppose you find that Checkpoint Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Checkpoint Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Checkpoint Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Checkpoint Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Checkpoint Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Checkpoint Therapeutics Lagged Returns
When evaluating Checkpoint Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Checkpoint Therapeutics stock have on its future price. Checkpoint Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Checkpoint Therapeutics autocorrelation shows the relationship between Checkpoint Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Checkpoint Therapeutics.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Checkpoint Stock Analysis
When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.